STAT+: Lilly adds highest Zepbound doses to DTC offering

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, let’s get straight to the news today.

The need-to-know this morning

• Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus a CVR potentially worth another $300 million. 
• Dyne Therapeutics received FDA clearance to seek accelerated approval for its drug to treat myotonic dystrophy type 1. However, the company pushed back the timing of the submission to “late 2026” from its previous guidance of “first half 2026.”

Duchenne families are fearful and divided after patient’s death

Following Sarepta Therapeutics’ disclosure that a second boy who took its gene therapy for Duchenne muscular dystrophy has died, the patient community is angry, fearful, and divided over whether to maintain hope in the therapy.

Continue to STAT+ to read the full story…